Spasmodic Dysphonia Clinical Trial
Official title:
Usability of Laryngeal Vibro-tactile Stimulation as a Non-invasive Treatment for the Voice Disorder Spasmodic Dysphonia
The general aim of the study is to provide evidence for usability and feasibility of applying vibro-tactile stimulation (VTS) at home as a non-invasive form of neuromodulation to improve speech in people with spasmodic dysphonia (SD). This work addresses a clinical need to develop alternative or auxiliary treatments for a rare voice disorder with very limited treatment options. Successful completion of the proposed work will be an important step in advancing laryngeal VTS as a therapeutic intervention for improving voice symptoms in SD.
Status | Recruiting |
Enrollment | 40 |
Est. completion date | October 20, 2024 |
Est. primary completion date | September 20, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Diagnosis of spasmodic dysphonia (laryngeal dystonia) for a minimum of 6 months with documented symptom relief after Botox injection. - Diagnosis is made by a voice disorder specialist. Exclusion Criteria: - Regular intake of benzodiazepines - Cognitive impairment: score < 27 on Mini-mental state examination - Identifies with a neurological or musculoskeletal impairment affecting speech motor function. These impairments may include a form of: Dyskinesia, Dystonia, Essential Tremor, Huntington's Disease, Multiple System Atrophy, Muscle Tension Dysphonia, Parkinsonism, Progressive Supranuclear Palsy, Spasticity, Intracranial Neoplasm (brain tumor), Spinal Neoplasm, Cerebrovascular Accident (Stroke), Mild Traumatic Brain Injury, Intracranial Hemorrhage, Multiple Sclerosis |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Perceived voice effort | Participants will rate their perceived effort level of vocalization on an ordinal scale of 0 to 10 (0 being with no effort and 10 being with maximal effort). The recordings will provide subjective impression of treatment. | 8 weeks | |
Secondary | The number of voice breaks | Prior to study begin, participants will receive a manual with instructions about the remote audio recording procedure. During pre- and post-application assessment, participants will record their voices using a voice recording application on their smartphone or digital tablet. The recordings will provide objective data on the number of voice breaks. | 8 weeks | |
Secondary | The duration of voice break | Prior to study begin, participants will receive a manual with instructions about the remote audio recording procedure. During pre- and post-application assessment, participants will record their voices using a voice recording application on their smartphone or digital tablet. The recordings will provide objective data on the duration of voice breaks. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02061943 -
Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change
|
N/A | |
Recruiting |
NCT05158166 -
DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
|
Phase 1/Phase 2 | |
Recruiting |
NCT05580302 -
Cortical Silent Period in Laryngeal Dystonia
|
||
Recruiting |
NCT05150106 -
Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
|
||
Recruiting |
NCT05216770 -
Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor
|
Early Phase 1 | |
Recruiting |
NCT05150093 -
Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
|
N/A | |
Completed |
NCT00713414 -
Role of Neurotransmission and Functional CNS Networks in Spasmodic Dysphonia
|
||
Completed |
NCT01961297 -
Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
|
Phase 2 | |
Completed |
NCT00118586 -
Neuropathology of Spasmodic Dysphonia
|
||
Not yet recruiting |
NCT04938154 -
A Phase 2 Trial of Deep Brain Stimulation for Spasmodic Dysphonia
|
Phase 2 | |
Active, not recruiting |
NCT03292458 -
Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
|
Phase 2/Phase 3 | |
Completed |
NCT02957942 -
rTMS in Spasmodic Dysphonia
|
N/A | |
Completed |
NCT02558634 -
Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
|
N/A | |
Terminated |
NCT00895063 -
Effect of Vocal Exercise After Botulinum Toxin Injection for Spasmodic Dysphonia
|
N/A | |
Completed |
NCT05158179 -
Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia
|
N/A | |
Not yet recruiting |
NCT06078527 -
Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort
|
N/A | |
Enrolling by invitation |
NCT05892770 -
Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia
|
Phase 1/Phase 2 | |
Completed |
NCT04648891 -
Spasmodic Dysphonia Pain
|
Phase 2/Phase 3 | |
Completed |
NCT03042962 -
Brain Networks in Dystonia
|
||
Completed |
NCT03746509 -
Laryngeal Vibration for Spasmodic Dysphonia
|
N/A |